Innovent's New Drug Application (NDA) for picankibart, an anti-IL-23p19 antibody, has been accepted by China's NMPA for treating moderate to severe plaque psoriasis.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.